N/A
N=90
Precision Assessment of Platelet Rich Plasma for Joint Preservation
Osteoarthritis
Bottom Line
View on ClinicalTrials.gov: NCT03460236 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Number of Participants With Successful Knee Pain Improvement Over 6 Months Following PRP Injections — 25 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Successful Knee Pain Improvement Over 6 Months Following PRP Injections |
25 | — |
| PRIMARY Number of Participants With Successful Knee Function Improvement Over 6 Months Following PRP Injections |
12 | — |
Summary
Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop knee OA at higher rates and younger ages than the population in general. For those with symptomatic early knee OA, who are years to decades away from meeting clinical indications for knee replacement surgery, knee injections have been a key treatment option. In recent years, platelet rich plasma (PRP) injections have gained increasing attention for improving pain and function in patients with knee OA. Basic science studies also suggest that PRP may also potentially stimulate repair responses to articular cartilage. However, the mechanisms of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used, the PRP composition differs between patients. It is also unknown whether these differences in PRP composition affect clinical outcomes. This study will address these gaps and provide critical new and objective information on PRP treatment effects in Veterans and additional women with early knee OA important to improving clinical use of this new treatment.
Eligibility Criteria
Inclusion Criteria
- symptomatic early knee OA
- full weight-bearing status
- have elected to receive PRP treatment
- Male veterans
- Female veterans
Exclusion Criteria
- inflammatory arthritis, gout or recurrent pseudogout
- symptomatic OA of other lower extremity joints
- BMI >35 kg/m2
- use of walking, orthopedic, or prosthetic assistive device
- severe systemic disease defined as American Society of Anesthesiologists (ASA) 3 or above56
- inability to have MRI
- pregnant or intending to become pregnant during the study
- predominantly patellofemoral disease
Data sourced from ClinicalTrials.gov (NCT03460236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.